Lee Chih-Hsien, Wei Jeng
Department of Cardiac Surgery, Tungs' Taichung Metro-Harbor Hospital; Department of Biological Science and Technology, National Chiao-Tung University; Department of Surgery, National Defense Medical Centre, Taiwan. Email:
Heart Centre, Cheng Hsin General Hospital, Taiwan.
Cardiovasc J Afr. 2016;27(4):e14-e16. doi: 10.5830/CVJA-2016-034. Epub 2016 Apr 12.
The prevalence of end-stage heart failure (HF) is on the increase, however, the availability of donor hearts remains limited. Left ventricular assist devices (LVADs) are increasingly being used for treating patients with end-stage HF. LVADs are not only used as a bridge to transplantation but also as a destination therapy. HeartMate II, a new-generation, continuous-flow LVAD (cf-LVAD), is currently an established treatment option for patients with HF. Technological progress and increasing implantation of cf-LVADs have significantly improved survival in patients with end-stage HF. Here we report a case of a patient with end-stage HF who was successfully supported using cf-LVAD implantation with adjuvant tricuspid valve repair in a general district hospital.
终末期心力衰竭(HF)的患病率正在上升,然而,供体心脏的可获得性仍然有限。左心室辅助装置(LVAD)越来越多地用于治疗终末期HF患者。LVAD不仅用作移植的桥梁,还用作终末期治疗。HeartMate II是一种新一代的连续流LVAD(cf-LVAD),目前是HF患者的既定治疗选择。技术进步和cf-LVAD植入数量的增加显著提高了终末期HF患者的生存率。在此,我们报告一例终末期HF患者,在一家普通地区医院通过cf-LVAD植入并辅助三尖瓣修复成功获得支持的病例。